Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro
A novel drug named Dasatinib is a highly potent ATP-competitive orally active dual Src/Abl kinase inhibitor with anti-proliferative activity against solid tumors and CML (chronic myeloid leukaemia) cell lines. Dasatinib has been shown to have preclinical activity against human prostate, breast, panc...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer-Verlag
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608870/ |